Skip to main content

How effective is Tzield?

Medically reviewed by Carmen Pope, BPharm. Last updated on May 3, 2023.

Official answer

by Drugs.com

Tzield has been shown to delay the progression of Stage 2 type 1 diabetes to Stage 3 type 1 diabetes by 25 months (approximately 2 years) in a phase 3, randomized, double-blind clinical trial. In an extended follow-up of this trial (duration 923 days), the average time to diagnosis of stage 3 type 1 diabetes was 59.6 months for Tzield-treated patients compared with 27.1 months for patients given a placebo (a difference of 32.5 months).

Another study that followed people for 7 years found persistent immunological responses and a reduced decline in C-peptide up to 7 years after the diagnosis of diabetes in people who respond to Tzield.

References
  • Herold KC, Bundy BN, Long SA, et al.. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381(7):603–613.
  • Hagopian, W., Ferry, R. J., Jr, Sherry, N., Carlin, D., Bonvini, E., Johnson, S., Stein, K. E., Koenig, S., Daifotis, A. G., Herold, K. C., Ludvigsson, J., & Protégé Trial Investigators (2013). Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes, 62(11), 3901–3908. https://doi.org/10.2337/db13-023
  • Sims, E. K., Bundy, B. N., Stier, K., Serti, E., Lim, N., Long, S. A., Geyer, S. M., Moran, A., Greenbaum, C. J., Evans-Molina, C., Herold, K. C., & Type 1 Diabetes TrialNet Study Group (2021). Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Science translational medicine, 13(583), eabc8980. https://doi.org/10.1126/scitranslmed.abc8980
  • Perdigoto, A. L., Preston-Hurlburt, P., Clark, P., Long, S. A., Linsley, P. S., Harris, K. M., Gitelman, S. E., Greenbaum, C. J., Gottlieb, P. A., Hagopian, W., Woodwyk, A., Dziura, J., Herold, K. C., & Immune Tolerance Network (2019). Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia, 62(4), 655–664. https://doi.org/10.1007/s00125-018-4786-9

Read next

Related medical questions

Drug information

Related support groups